efficacy of aroma in preventing nausea and vomiting (NV) related to dimethyl sulfoxide (DMSO) in 69 autologous HCT (auto-HCT) patients undergoing high myeloablative conditioning regimens, found delayed NV in 90% patients.
Introduction
The occurrence of chemotherapy-induced nausea and vomiting (CINV) is usually biphasic, consisting of the first 24 hours following chemotherapy (acute CINV) and lasting up to 5-7 days after chemotherapy (delayed CINV) (1) . Delayed CINV continues to be an important problem in patients who receive moderate (MEC) to high (HEC) emetogenic chemotherapy.
López-Jiménez et al (2) found that 90% of all patients undergoing autologous or allogeneic hematopoietic cell transplant (HCT) and 55% of acute leukemia patients treated with multiple-day chemotherapy complained of nausea. In the 5 days following treatment, approximately 35% of patients with leukemia and only 10% of HCT patients were completely protected from nausea and vomiting without rescue therapy (2) . Our recent randomized controlled trial (3) , exploring the patients randomized to aprepitant still complained of delayed nausea and vomiting, respectively (7) .
The problem is further complicated by a lack of specific guidelines for hematological patients and by variable compliance with the available guidelines. A recent prospective observational study in 8 European countries (8) in 991 chemotherapy-naïve adults undergoing HEC or MEC showed low adherence to antiemetic guidelines, varying between the acute and delayed phases, and emetogenicity of regimens. A guideline-consistent CINV prophylaxis (GCCP) was implemented for 55% and 46% patients during the acute and delayed phases, respectively, and was lower in HEC compared with MEC regimens (21 [7. 3%] vs. 133 [46.3%]), both in the acute and delayed phase. Other studies (9) showed an 11% adherence to the Multinational Association of Supportive Care in Cancer (MASCC) guidelines (10) for the prevention of delayed CINV in 75 HEC patients, with frequent omissions of corticosteroids and an overuse of 5HT 3 -RAs. Poor adherence to dexamethasone and NK1-RA continues to be a widespread problem (11) (12) (13) .
However, adherence to antiemetic guidelines improved the control of CINV. In 2 studies (8, 13) , GCCP-treated patients reported less delayed CINV than those without the recommended prophylaxis. Gilmore and colleagues (13) found patients receiving a GCCP to have a 31% increase in delayed CINV protection compared with those without the recommended prophylaxis (adjusted odds ratio [OR] = 1.31, 95% confidence interval [95% CI], 1.07-1.69, p = 0.037). A similar although not statistically significant advantage was found by Aapro et al (OR = 1.27, 95% CI, 0.92-1.75, p = 0.142) (8) .
Despite many studies (4, 14) exploring the incidence of acute and delayed CINV associated with high-dose conditioning regimens for HCT, none described their daily clinical course in a transplant setting. This study aimed to describe the course of nausea, vomiting and retching over the 5 days following auto-HCT.
methods

Study design
This was a longitudinal observational exploratory analysis of data derived from a multicenter randomized controlled clinical trial that was conducted between June 2012 and January 2013 (3). The study was approved by the ethics committee of all the participating centers. The patient data were analyzed as a merged prospective cohort.
Primary study
A randomized 3-arm open-label trial in 4 Italian large bone marrow transplant centers was conducted. The aim of the primary study was to assess the effectiveness of orange aroma in preventing NV related to DMSO in 69 auto-HCT patients. DMSO is the cryopreservative used to store hematopoietic cells and is indeed associated with frequent NV partly related to its characteristic effect in producing garlic-like breath in the patient (15) . The smell and flavor of orange had been hypothesized to reduce the patient's perception of its unpleasant odor (16, 17) . Patients were randomized to orange (n = 23) or noncitrus ice lollies (n = 21) and routine treatment (deep breaths, n = 25).
Data on NV and retching were collected for up to 5 days after infusion. Patients completed 6-day daily diaries beginning on the transplant day and continuing until day 5, reporting their nausea intensity every 4 hours (numeric rating scale [NRS] 0-100) along with vomiting and retching (VR) episodes.
Exploratory secondary analysis
The aim of the exploratory secondary analysis was to discover the course of nausea, vomiting and retching over the 5 days following auto-HCT, regardless of the treatment received (i.e., orange ice lollies, noncitrus ice lollies, deep breaths) in the primary study. Patients' data were analyzed as a merged prospective cohort controlling for the treatment.
Data collection
Data on NV and retching were collected up to 5 days after infusion, meaning an observation period from 2 to 7 days after the end of the conditioning regimen, based only on chemotherapy in this group of patients. The transplant generally takes place 24 hours after the end of chemotherapy (18) .
Antiemetic prophylaxis was collected from clinical records. Nausea was considered absent if <5 on NRS 0-100, controlled between 5-25 and uncontrolled if >25 (2) . Distinct VR episodes were separated by at least 1 minute. VR episodes were considered controlled if there were ≤2 episodes/day (vomiting or retching) (2) .
The emetogenic potential of each drug was defined according to the MASCC guidelines (10) . The emetogenicity of the combined regimens was defined as follows: not increased by the minimal emetogenic agent and increased by 1 level from the low emetogenic agent compared with the most emetogenic agent administered; the moderately and highly emetogenic agent increased the emetogenicity of each drug by 1 level (19) . According to MASCC guidelines (10), the following regimens are recommended in the delayed phase: dexamethasone days 2-4, plus aprepitant days 2-3 after chemotherapy for HEC, and aprepitant, dexamethasone or a 5HT 3 RA on days 2-3 after chemotherapy for MEC.
Adherence to the recommended prophylaxis was scored as yes/no. Patients were classified as receiving GCCP or guideline-inconsistent CINV prophylaxis (GICP) if they were given or not the recommended drugs daily, respectively (8) .
Data analysis
Descriptive statistics were adopted. Intensity of the nausea was measured over 24 hours and expressed as the median and interquartile range (IQR), and the episodes of VR were expressed as sums. Categorical variables were summarized as sums and percentages, and Fisher's exact test was used for comparisons.
A correlation structure was specified to account for repeated measures over time (24, 48, 72, 96 and 120 hours after reinfusion) for the same patient. A continuous-time autoregressive of order 1 correlation structure resulted in the best model fit, based on the Akaike information criterion. We controlled by age, sex, treatment and number of stem cell bags infused. The linear relationship of nausea intensity over time was assessed using restricted cubic splines and was tested with a Wald chi-square test. The data were analyzed with R version 2.15 (20) . All p values were 2-sided, and a p value of less than 0.05 was considered significant.
results
Over 60% (n = 43) of patients were male, and approximately 80% (n = 56) had HEC. More than half (n = 32) of HEC patients were given a high-dose melphalan, whereas all MEC patients were given melphalan at a lower dose. The patient characteristics and treatments administered are shown in Table I .
All patients except 1 received methylprednisolone 125 mg on the transplant day. Before reinfusion, hydrocortisone 200 mg was administered alone in a MEC patient and in combination with methylprednisolone in 15 HEC patients.
Nearly all patients (93%) received 5HT 3 -RA. Overall, less than 20% received a guideline-recommended antiemetic prophylaxis. Only 7 HEC patients received aprepitant, and 1 patient alone received dexamethasone. No HEC patients were given prophylactic treatment that was adherent to the MASCC guidelines. In contrast, all MEC patients except 1 received postchemotherapy prevention for delayed CINV with a 5HT 3 -RA (Tab. I). Two or more antiemetic agents were administered to 12 patients (17%).
At the end of the transplant, 51 patients (74%) reported no nausea, 10 reported controlled nausea and 7 reported uncontrolled nausea (information missing for 1 patient).
The course of nausea was similar for HEC and MEC patients, starting to increase on the second day after reinfusion, peaking between 72 and 96 hours, and decreasing on the fifth day. Longitudinal regression analyses showed an average increase of 3.8 points in nausea intensity every 24 hours.
The overall pattern for vomiting was similar, while retching episodes remained unchanged after the third day following transplant. The results are summarized in Table II .
During the 5-day observation period, 52 patients (75%) reported nausea, and over 60% reported (n = 44) vomiting or retching. At least once in the 5 days after transplant, 24 patients (35%) had uncontrolled nausea and 40% (n = 28) had more than 2 episodes of vomiting or retching. Overall, 32 patients had NV or retching. However, 9 patients experienced emesis or retching without nausea, and 18 (26%) experienced nausea without vomiting or retching. At least once, 41 HEC (73%) and 11 MEC (85%) patients reported nausea, which was uncontrolled in 19 HEC (34%) and in 5 MEC patients (38%). Similarly, 36 HEC (64%) and 8 MEC patients (62%) reported emetic episodes (Tab. III). More MEC patients reported uncontrolled vomiting or retching compared with HEC patients (7 [54%] vs. 21 [38%]), but the emetic episodes per day per patients between the 2 groups were similar (1.2 vs. 1.3). However, no significant differences were found between the HEC and MEC patients (Tab. III).
Of 12 patients treated with GCCP, 9 (75%) reported no uncontrolled vomiting or retching episodes vs. 32 (56%) in the GICP group, whereas no difference was observed in the control of nausea between patients exposed or not to the recommended prophylaxis. However differences were not significant (p = 1.000; data not shown). 
Discussion
This study investigated the course of NV over the 5 days following auto-HCT. About 65% of patients had multiple myeloma and almost all received auto-HCT with melphalan, which is the treatment of choice in patients younger than 65 years according to a recent consensus statement (21) .
We observed a greater incidence of delayed NV compared with previous studies (6, 7) , possibly due to a longer observation period after the end of the conditioning regimen (7 days vs. 5 days) (22, 23) . Similar to other studies (22, 23) , we found no significant differences in delayed nausea between HEC and MEC patients. Both studies (22, 23) showed that HEC patients had a higher risk of delayed emesis, while no differences were observed in our study for vomiting and retching. However, our MEC subgroup was limited in size, and the study did not have enough power for this analysis.
The clinical course of delayed CINV described in this study differs from that portrayed by Bloechl-Daum et al (22) in their prospective study of 298 naïve patients with different cancers. They showed NV plateauing between days 2 and 3 after chemotherapy and slightly decreasing between days 3 and 4. However, we found the peak on day 6 after the end of the conditioning regimen, with an almost 50% decrease in the nausea intensity on day 7. However, Bloechl-Daum et al (22) only included patients receiving single-day chemotherapy, while 35% of our patients received multiple-day chemotherapy, which may explain the delay in reaching the peak.
Our findings highlight the importance of a separate assessment for vomiting and retching because their pathways most likely differ. Vomiting decreased along with nausea, whereas retching remained significantly unchanged when patients had no more matter to expel. Hence, routine assessment of retching may avoid the risk of underestimating adverse chemotherapy effects. However, 40% of our patients complained of nausea without emesis or vice versa, confirming that the neurotransmitter pathways of NV are most likely not identical in spite of NV being correlated and their clinical courses being similar.
The poor adherence to guidelines for delayed antiemetic prophylaxis limited to HEC patients has already been shown in other studies: according to Gomez et al (11) , the rate of appropriate administration of NK1-RA was approximately 10%. In addition, dexamethasone was almost never administered, similar to what was found in previous studies (8, 11, 12, 24) where administration of corticosteroids ranged between 10% and 97% of patients, depending on the emetogenic potential of chemotherapy and the line of treatment. However, immunosuppressed transplant patients are at higher risk of infections, and steroids were most likely not used to avoid increasing this risk. This may explain the overuse of serotonin antagonists and the higher adherence to the guidelines in MEC regimens compared with HEC regimens, because 5HT 3 -RAs represent an alternative to dexamethasone for delayed CINV only in MEC-treated patients. The differences in nausea, vomiting and retching between GCCP and GICP patients cannot be commented on, as information about the antiemetic regimens as well as the control of CINV during the acute phase was not collected in the main study. The current antiemetic guidelines are aimed only at emesis prevention, and our, as well as Aapro et al's, findings (8) , suggest that nausea and emesis are separate phenomena requiring different remedies. However, other causes, such as mucositis (25) , the preliminary symptoms of which are nausea and abdominal cramps, may have contributed to the increased incidence of NV in our study.
These exploratory data analyses were limited by the small sample, which did not allow subgroup comparisons, and the fact that antiemetic doses were not recorded. Moreover, the etiology of NV in HCT recipients is multifactorial and includes damage to the gastrointestinal lining that may result in a continual source of serotonin release, side effects of prophylactic antibiotics and narcotic analgesics, and the high-dose preparative regimens that lead to a poor end-of-regimen control rate. However, this study contributes to our knowledge of the course of NV and retching in transplant patients who are usually heavily treated and receive multiple-day chemotherapy regimens.
In summary, delayed CINV continues to be a challenge for health care professionals working with auto-HCT patients despite the progress in antiemetic prophylaxis. In auto-HCT patients, the course of NV differs from that for other patients receiving chemotherapy, with a delayed peak most likely due to multidrug regimens. Further studies are warranted to define the best antiemetic regimen in this population and to explore the control of symptoms in auto-HCT patients treated with GCCP compared with GICP.
Finally, nausea and vomiting were confirmed to be 2 separate entities. Similarly, retching was shown as a symptom different from vomiting. As not only vomiting but also nausea and retching create discomfort for patients and have an impact on their quality of life, all 3 of these symptoms should be assessed, prevented and treated separately in routine clinical practice.
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